# Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) – DMID 21-0004

> **NIH NIH UM1** · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2021 · $625,430

## Abstract

PROJECT SUMMARY
This is an observational, non-interventional, prospective cohort study designed to collect clinical information
and specimens to evaluate the immune responses from approximately 2,000 study
participants following maternal receipt of licensed or EUA SARS-CoV-2 vaccines. Pregnant and
postpartum individuals and their infants will be screened for study interest and eligibility and
enrolled. Study participant groups are as follows:
Approximately 2,000 study participants will be enrolled into one of four subject groups:
 Group 1: Individuals who receive a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-
 2) vaccine during pregnancy (up to150 individuals per vaccine type)
 Group 2: Individuals who receive a SARS-CoV-2 vaccine postpartum (up to 50 individuals per vaccine
type)
 Group 3: Infants of individuals who receive vaccine during pregnancy (approximately 150 infants per
 vaccine type)
 Group 4: Infants of individuals who receive vaccine postpartum (approximately 50 infants per vaccine
type)
Primary objectives are:
• Immunogenicity: To describe the kinetics and durability of maternal serum antibodies following receipt of
 SARS-CoV-2 vaccine in individuals vaccinated during pregnancy, by vaccine type and platform.
• Immunogenicity: To describe the transplacental antibody transfer of SARS-CoV-2 antibodies among
 individuals vaccinated during pregnancy, overall and by vaccine type and platform.
• Immunogenicity: To describe the kinetics and durability of serum SARS-CoV-2 antibodies in infants of
mothers vaccinated during pregnancy, by vaccine type and platform.

## Key facts

- **NIH application ID:** 10416210
- **Project number:** 3UM1AI148574-02S1
- **Recipient organization:** NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- **Principal Investigator:** Mark Joseph Mulligan
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $625,430
- **Award type:** 3
- **Project period:** 2021-06-29 → 2023-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10416210

## Citation

> US National Institutes of Health, RePORTER application 10416210, Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) – DMID 21-0004 (3UM1AI148574-02S1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10416210. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*